Take­da wins pri­or­i­ty re­view for $400M col­orec­tal can­cer drug, li­censed from Hutchmed in Jan­u­ary

Take­da and Hutchmed scored a pri­or­i­ty re­view Thurs­day af­ter­noon for a col­orec­tal can­cer drug, the com­pa­nies an­nounced.

The ex­per­i­men­tal drug in ques­tion is fruquin­tinib, pre­vi­ous­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER